Thomas Anderson Biography and Net Worth

Director of Zevra Therapeutics

Thomas D. Anderson has served as a director of our Company since August 2023. Mr. Anderson is a 35-year veteran of the biopharma industry and has led and been a part of high-growth organizations for much of his career. Mr. Anderson has served as chief executive officer and director of SwanBio Therapeutics since September 2019 until semi-retirement in October 2023, and subsequently resigned his board directorship in March 2024. Prior to that, he served as the chief commercial strategy officer of Sage Therapeutics, Inc. from 2014 to 2018. Between 2004 and 2014, Mr. Anderson was a senior operating executive with Shire Pharmaceuticals Group in a number of operational and strategic roles in both rare diseases and specialty pharmaceuticals. Prior to Shire, he spent 17 years at Johnson & Johnson’s pharmaceutical companies, McNeil and Janssen, in various business capacities. Mr. Anderson is also an investor partner at Robin Hood Ventures in Philadelphia, Pennsylvania. Mr. Anderson earned his MBA from the University of Notre Dame’s Mendoza College of Business Administration. He received his BS in civil engineering from the P.C. Rossin College of Engineering at Lehigh University. Our Board believes that Mr. Anderson’s significant leadership experience in the biotechnology industry and his experience in rare disease qualifies him to serve on the Board.

What is Thomas Anderson's net worth?: The estimated net worth of Thomas Anderson is at least $173.20 thousand as of July 16th, 2024. Anderson owns 20,000 shares of Zevra Therapeutics stock worth more than $173,200 as of December 4th. This net worth estimate does not reflect any other assets that Anderson may own. Learn More about Thomas Anderson's net worth.
How do I contact Thomas Anderson?: The corporate mailing address for Anderson and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on Thomas Anderson's contact information.
Has Thomas Anderson been buying or selling shares of Zevra Therapeutics?: Thomas Anderson has not been actively trading shares of Zevra Therapeutics during the last ninety days. Most recently, on Tuesday, July 16th, Thomas Anderson bought 10,000 shares of Zevra Therapeutics stock. The stock was acquired at an average cost of $6.81 per share, with a total value of $68,100.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company's stock, valued at $136,200. Learn More on Thomas Anderson's trading history.
Who are Zevra Therapeutics' active insiders?: Zevra Therapeutics' insider roster includes Thomas Anderson (Director), John Bode (Director), R. Clifton (Chief Financial Officer & Treasurer), Neil McFarlane (President & Chief Executive Officer), Timothy Sangiovanni (Senior Vice President, Corporate Controller), Joshua Schafer (Chief Commercial Officer), and Corey Watton (Director). Learn More on Zevra Therapeutics' active insiders.
Are insiders buying or selling shares of Zevra Therapeutics?: In the last year, Zevra Therapeutics insiders bought shares 4 times. They purchased a total of 18,475 shares worth more than $152,485.25. In the last year, insiders at the sold shares 5 times. They sold a total of 105,273 shares worth more than $885,165.78. The most recent insider tranaction occured on October, 10th when CEO Neil F Mcfarlane sold 19,500 shares worth more than $210,990.00. Insiders at Zevra Therapeutics own 2.4% of the company. Learn More about insider trades at Zevra Therapeutics.
Information on this page was last updated on 10/10/2025.

Thomas Anderson Insider Trading History at Zevra Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/16/2024	Buy	10,000	$6.81	$68,100.00	20,000

Thomas Anderson Buying and Selling Activity at Zevra Therapeutics

Zevra Therapeutics Company Overview

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Today's Range

Now: $8.66

$8.48

$8.80

50 Day Range

MA: $9.79

$8.17

$11.78

2 Week Range

Now: $8.66

$6.19

$13.16

Volume

823,188 shs

Average Volume

1,395,027 shs

Market Capitalization

$487.56 million

P/E Ratio

18.43

Dividend Yield

N/A

Beta

1.01